Hepatitis
Also known as: Hepatic infection, Liver, Hepatic, Biliary, Hepar
Methodology & AI Transparency ⓘ
Hepatitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is hepatitis? Hepatitis is inflammation of the liver .
- 2 Real-world patient consensus: Synonyms for Hepatitis (K75.9): Hepatic infection, Liver, Hepatic (Liver & Hepatology).
- 3 Typical cash cost range: Differential triage of Hepatitis (K75.9) utilizes metabolic insulin-sensitizing weight in Hepatitis (K75.9: optimization).
- 4 Top reported side effects / signs: Objective lab/clinical target for Hepatitis: ALT, AST, Alkaline in Hepatitis (K75.9: Phosphatase & GGT) (ALT < 25 U/L (men) / < 19 U/L (women) (K75.9)) and FIB-4 Hepatic Fibrosis in Hepatitis (K75.9: Index).
Ask our AI Specialists anything about Hepatitis
What Is Hepatitis?
What is hepatitis? Hepatitis is inflammation of the liver . Inflammation is swelling that happens when tissues of the body are injured or infected. It can damage your liver. This swelling and damage can affect how well your liver functions. Hepatitis can be an acute (short-term) infection or a chronic (long-term) infection. Some types of hepatitis cause only acute infections. Other types can cause both acute and chronic infections. What causes hepatitis? There are different types of hepatitis, with different causes: Viral hepatitis is the most common type. It is caused by one of several viruses -- hepatitis viruses A , B , C , D, and E.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Hepatitis (ICD-10 K75.9) is driven by hepatic stellate-cell fibrosis [Hepatitis K75.9]; Cross-referenced with NIH MeSH (Hepatitis), specialists in Liver, Gallbladder & Pancreatic Health monitor FIB-4 Hepatic Fibrosis in Hepatitis (K75.9: Index) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Alcoholic hepatitis is caused by heavy alcohol use
- • Toxic hepatitis can be caused by certain poisons, chemicals, medicines, or supplements
- • Presentation of Hepatitis (K75.9): asymptomatic elevation of in Hepatitis (K75.9: liver transaminases)
- • Secondary Hepatitis clinical sign: right upper quadrant in Hepatitis (K75.9: fullness or sharp)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hepatitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | K75.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Liver, Gallbladder & Pancreatic Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: ALT, AST, Alkaline in Hepatitis (K75.9: Phosphatase & GGT) | ALT < 25 U/L (men) / < 19 U/L (women) (K75.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: FIB-4 Hepatic Fibrosis in Hepatitis (K75.9: Index) | < 1.30 (K75.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total Bilirubin & in Hepatitis (K75.9: Albumin) | Bilirubin 0.2–1.2 mg/dL; Albumin >= 4.0 g/dL (K75.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hepatitis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Epivir (Lamivudine) Epivir • RxCUI 199147-B49702205 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 87% | $0.2339 | $ 12.80 /mo |
| Vemlidy (Tenofovir Alafenamide) Vemlidy • RxCUI RXN-B619582301 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 77% | $49.0404 | $ 640.00 /mo |
| Tenofovir Disoproxil Fumarate Tablets Tenofovir Disoproxil Fumarate Tablets Generic • RxCUI RXN-62135466-2958 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 76% | $0.2938 | $ 20.40 /mo |
| Cimduo (Lamivudine and Tenofovir Disoproxil Fumarate) Cimduo • RxCUI 2003255 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 75% | $0.2339 | $ 25.34 /mo |
| Elbasvir and Grazoprevir Zepatier • RxCUI 1734636 | Hepatitis C Virus NS5A Inhibitor | 84% | $0.9200 | $ 45.76 /mo |
| Nabi-Hb (Hepatitis B Immune Globulin (Human)) Nabi-Hb • RxCUI 1658127 | Human Immunoglobulin | 83% | $0.9900 | $ 79.78 /mo |
| Mavyret (Glecaprevir and Pibrentasvir) Mavyret • RxCUI RXN-B00742625 | Hepatitis C Virus NS3/4A Protease Inhibitor | 80% | $152.8336 | $ 640.00 /mo |
| Combivir (Lamivudine and Zidovudine) Combivir • RxCUI 200082-B49702202 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 79% | $0.2339 | $ 13.61 /mo |
| Zepatier (Elbasvir and Grazoprevir) Zepatier • RxCUI 1734642 | Hepatitis C Virus NS5A Inhibitor | 92% | $3.4900 | $ 259.78 /mo |
| Hepatitis B Immune Globulin (Human) Nabi-Hb • RxCUI 1658125 | Human Immunoglobulin | 91% | $1.3600 | $ 63.58 /mo |
| Harvoni (Ledipasvir and Sofosbuvir) Harvoni • RxCUI RXN-B619581803 | Hepatitis C Virus NS5A Inhibitor | 86% | $3.0900 | $ 230.98 /mo |
| Vosevi (Sofosbuvir, Velpatasvir, and Voxilaprevir) Vosevi • RxCUI RXN-B619582401 | Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor | 74% | $278.3091 | $ 640.00 /mo |
| Ledipasvir and Sofosbuvir Harvoni • RxCUI RXN-619581803-2954 | Hepatitis C Virus NS5A Inhibitor | 91% | $0.9600 | $ 47.38 /mo |
| Tenofovir Alafenamide Vemlidy • RxCUI RXN-619582301-2546 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 79% | $49.0404 | $ 185.00 /mo |
| Entecavir Anhydrous Baraclude • RxCUI RXN-42494458-1840 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 91% | $0.3119 | $ 28.39 /mo |
| Sofosbuvir Sovaldi • RxCUI RXN-619581501-2393 | Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor | 77% | $278.3091 | $ 185.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hepatitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic: What a 2,178-Participant Study Found This study evaluated the efficacy of GLP-1RAs in patients with NAFLD and NASH. Primary care diabetes • 2024-06-15 • Meta-Analysis | N = 2,178 | 99/100 | PMID 38555202 ↗ |
| New Insights on Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic: What a 1,778-Participant Study Found This study did not demonstrate the efficacy of CVC for treating liver fibrosis assessed by histology in adults with NASH; however, CVC was safe and well tolerated in patients with NASH and liver fibrosis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2024-01-15 • Phase III Randomized Trial | N = 1,778 | 96/100 | PMID 37061109 ↗ |
| New Insights on Immunogenicity and safety of concomitant vaccines given with 20-valent: What a 1,997-Participant Study Found Immune responses to routine children vaccines given with PCV20 were noninferior to those when given with PCV13. Vaccine • 2025-12-05 • Phase III Randomized Trial | N = 1,997 | 96/100 | PMID 41187484 ↗ |
| New Insights on Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated: What a 1,197-Participant Study Found In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. The New England journal of medicine • 2025-06-05 • Phase III Randomized Trial | N = 1,197 | 96/100 | PMID 40305708 ↗ |
| New Insights on Long-term protection from naturally acquired immunity against hepatitis E virus: What a 3,194-Participant Study Found Six were hospitalized, all of whom were baseline seronegative. Nature communications • 2025-12-17 • Phase III Randomized Trial | N = 3,194 | 96/100 | PMID 41407683 ↗ |
Hepatitis Patient Community & “People Like Me” Threads
Filter Hepatitis community threads and patient logs by age, biological sex, dosage, and treatment duration.